Restoring SMN Expression: An Overview of the Therapeutic Developments for the Treatment of Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is an autosomal recessive neurodegenerative disorder and one of the most common genetic causes of infant death. It is characterized by progressive weakness of the muscles, loss of ambulation, and death from respiratory complications. SMA is caused by the homozygous dele...
Main Authors: | Tejal Aslesh, Toshifumi Yokota |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-01-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/11/3/417 |
Similar Items
-
What could be the function of the spinal muscular atrophy-causing protein SMN in macrophages?
by: Ines Tapken, et al.
Published: (2024-05-01) -
Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug‐like compounds
by: Jonathan J. Cherry, et al.
Published: (2013-06-01) -
Assessment of Nuclear Gem Quantity for Evaluating the Efficacy of Antisense Oligonucleotides in Spinal Muscular Atrophy Cells
by: Haya Al-Hilal, et al.
Published: (2024-01-01) -
History of development of the life-saving drug “Nusinersen” in spinal muscular atrophy
by: Jiaying Qiu, et al.
Published: (2022-08-01) -
Molecular Pathogenesis and New Therapeutic Dimensions for Spinal Muscular Atrophy
by: Andrés López-Cortés, et al.
Published: (2022-06-01)